利培酮
耐受性
阳性与阴性症状量表
氯氮平
安慰剂
锥体外系症状
心理学
精神分裂症(面向对象编程)
精神病理学
内科学
辅助治疗
精神科
非定型抗精神病薬
医学
抗精神病药
精神病
不利影响
替代医学
病理
作者
Abdülkadir Yağcioğlu,Berna Binnur Akdede,Tolga I. Turgut,Mevhibe Tumuklu,M. Kâzım Yazıcı,Köksal Alptekin,Aygun Ertugrul,Karu Jayathilake,Aytaç Göğüş,Zeliha Tunca,Herbert Y. Meltzer
摘要
Several open trials and case studies have reported beneficial effects following the addition of risperidone for partial responders to clozapine. The purpose of this study was to carry out a placebo-controlled, randomized, double-blind trial of the efficacy, safety, and tolerability of adjunctive treatment with risperidone in patients with schizophrenia partially responsive to clozapine.In this 6-week double-blind study, 30 patients with DSM-IV schizophrenia who had partial response to clozapine despite being treated for a mean of 32 months were randomly assigned to risperidone (N = 16) up to 6 mg/day or placebo (N = 14). Efficacy assessments included the Positive and Negative Syndrome Scale (PANSS), the Calgary Depression Scale, the Clinical Global Impressions-Severity of Illness scale, the Global Assessment of Functioning scale, and the Quality of Life Scale. A variety of safety and tolerability measures were also obtained. Data were collected between November 2001 and July 2003.Significant improvement was noted in both groups on a variety of measures of psychopathology, but there was significantly greater improvement in the placebo-treated patients on the primary outcome measure, the PANSS positive symptom subscale. There were no significant differences between the treatment groups regarding extrapyramidal symptoms, weight gain, vital signs, serum clozapine levels, and QTc interval. The only side effect significantly more severe in risperidone-treated compared to placebo-treated patients was sedation. The patients treated with risperidone developed significant increases in plasma prolactin levels.Adjunctive risperidone treatment in schizophrenia patients partially responsive to clozapine does not significantly improve psychopathology or quality of life compared to placebo in a 6-week period.
科研通智能强力驱动
Strongly Powered by AbleSci AI